Masimo Corporation Issues Supplemental Disclosures Regarding Pending Merger

Masimo Corporation (NASDAQ: MASI) has issued a supplemental report on Form 8-K dated April 23, 2026, providing important updates and clarifications for shareholders ahead of its proposed merger with Danaher Corporation. This article details the key points and implications for investors.

Key Points from the Report

• Supplemental Disclosures to Proxy Statement: Masimo voluntarily provided additional information to supplement its Definitive Proxy Statement regarding the merger with Danaher Corporation. The company maintains these disclosures are not required by law, but are intended to mitigate risks of litigation or delay to the merger process.
• Legal Actions and Shareholder Letters: Masimo faces legal challenges (“Actions”) and shareholder letters alleging inadequate disclosure around the merger. The company believes these claims are without merit, stands by the completeness of its Proxy Statement, and denies any wrongdoing or necessity for further disclosure. However, it has chosen to supplement the Proxy Statement solely to reduce risk and uncertainty.
• No Impact on Merger Terms or Timing: The supplemental disclosures do not change the consideration to be paid to Masimo shareholders or alter the timing of the Special Meeting to vote on the merger. The Board continues to recommend shareholders vote “FOR” the merger agreement and related proposals.
• Background of the Merger: The report amends and supplements several paragraphs in the Proxy Statement, including details on the formation of a Board “Working Group” to coordinate the sale process and regular updates to the Board. Notably, members of the Working Group did not receive additional compensation for their roles.
• Negotiations with Party F: The report provides further detail on negotiations with Party F, including the sending of a draft non-disclosure agreement (with standard standstill provisions) and a “clean team” agreement for reviewing competitively sensitive information. On February 13, 2026, Party F submitted a non-binding proposal to Masimo.
• Centerview Partners Analysis: The report amends the Proxy Statement’s table summarizing precedent transactions used by Centerview Partners LLC in its fairness opinion. Details include transaction dates, targets, acquirers, transaction values, and EBITDA multiples from relevant healthcare and life sciences deals.
• Securities and Exchange Details: Masimo’s common stock (\$0.001 par value) continues to trade under the symbol MASI on Nasdaq. The company states it is not an emerging growth company as defined by securities regulations.
• No Written or Soliciting Communications: The filing explicitly states it is not intended as written communications or soliciting material under SEC rules, nor as pre-commencement tender offers under relevant Exchange Act rules.
• Forward-Looking Statements: The report includes cautionary language regarding forward-looking statements, noting risks such as litigation, regulatory developments, and the possibility that merger benefits may not be realized as expected.
• Access to Documents: Shareholders can access Masimo’s SEC filings free of charge on both the SEC website and Masimo’s investor relations page.
• Participants in Solicitation: Masimo, Danaher, and their respective directors and officers may be considered “participants” in the proxy solicitation for the merger.
• No Offer or Solicitation: The communication clarifies it is not an offer to buy or sell securities or solicit votes in any jurisdiction.

Important Considerations for Shareholders

• Legal Risks: While Masimo believes the lawsuits and shareholder letters are meritless, the existence of legal challenges may introduce uncertainty and potential costs to the merger process. However, the company’s proactive disclosure aims to reduce these risks.
• Board Recommendation: The Board strongly recommends voting “FOR” the merger and related proposals, emphasizing that supplemental disclosures do not affect the terms or timing of shareholder consideration.
• Potential Price Sensitivity: The merger with Danaher is a major transaction for Masimo. Any developments—such as additional lawsuits, regulatory issues, or changes in negotiation details—could materially impact share value. Investors should closely monitor future communications and filings for further updates.
• Comparative Transaction Multiples: The updated Centerview table provides context for Masimo’s valuation relative to precedent transactions, which may inform shareholder views on the fairness of merger consideration.

Conclusion

Masimo’s supplemental 8-K filing underscores its commitment to transparency and risk mitigation in the merger process. While the company asserts the merger terms remain unchanged and claims are without merit, shareholders should be aware of ongoing legal challenges and their potential to affect the deal’s timing, costs, and ultimate outcome. The Board’s strong endorsement of the merger, coupled with detailed disclosures and comparative transaction data, aim to reassure investors ahead of the Special Meeting.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Shareholders should review the official SEC filings and consult their own financial advisors before making decisions related to the Masimo-Danaher merger. All forward-looking statements are subject to risks and uncertainties as described in the company’s filings.

View MASIMO CORP Historical chart here